 Suboptimal response vaccine drug users Fifty-five drug users community drug detoxification hepatitis virus HBV recombinant yeast-derived vaccine Engerix Smith Kline Biologicals Belgium months micrograms vaccine deltoid patients serum HBV markers antibody antigen anti-HBc anti-HBc antibody surface antigen anti-HBs values protective value mIU/mL healthy controls parallel month ie month third dose vaccine drug users HBV markers isolated anti-HBc anti-HBc nonprotective anti-HBs protective anti-HBs titers equal mIU/mL controls month rates drug users HBV marker anti-HBc anti-HBc anti-HBs controls drug users likely evidence prior HBV infection anergy tests unresponsiveness vaccine drug users due altered immunity